View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Általános Orvostudományi Kar Orvosi Laboratórium Analitikai Tanszék Debrecen Pf. 55. 4012
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A vér magas húgysav-koncentrációja több megbetegedés (veseelégtelenség, köszvény, tumorlízis- és metabolikus szindrómák) patomechanizmusában játszik szerepet. A tumorlízis-szindróma a tumoros betegeknél spontán vagy kezelés következtében alakul ki, egyik markere a hyperurikaemia. A különböző megbetegedésekben kialakuló hyperurikaemia prevenciójára, illetve terápiájára ma már egyre gyakrabban alkalmazzák a rekombináns húgysavoxidáz- (rasburicas-) terápiát, amely hatékonyan csökkenti a szérumhúgysav-koncentrációt. A terápia során a rasburicas a húgysavat jól oldódó allantoinná alakítja, amely a vese révén eliminálódik. A reakcióban keletkező nagy koncentrációjú hidrogén-peroxid a vörösvértestek oxidatív hemolízisét okozhatja, ha a hidrogén-peroxid-elimináló enzimek (glükóz-6-foszfát-dehidrogenáz, kataláz) aktivitása jelentősen csökken. Ezért ezen enzimek aktivitásának mérése ajánlható a terápia megkezdése előtt. A rasburicasterápia monitorozása a szérumhúgysav-koncentráció mérésével történhet. A Magyarországon végzett húgysav-meghatározások több mint 95%-a szintén az urikázeljárást alkalmazza, és a keletkező hidrogén-peroxidot méri, ezért a monitorozáskor a preanalitikai tényezőket, valamint az aszkorbinsav- és a rasburicasterápia során keletkezett hidrogén-peroxid-interferenciát figyelembe kell venni.

  • Vitart, V., Rudan, I., Hayward, C. és mtsai: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Gen., 2008, 40 , 437–442.

    Hayward C. , 'SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout ' (2008 ) 40 Nature Gen. : 437 -442.

    • Search Google Scholar
  • Döring, A., Gieger, C., Mehta, D. és mtsai: SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Gen., 2008, 40 , 430–436.

    Mehta D. , 'SLC2A9 influences uric acid concentrations with pronounced sex-specific effects ' (2008 ) 40 Nature Gen. : 430 -436.

    • Search Google Scholar
  • Ford, E. S., Chaoyang, L., Coojk, S. és mtsa: Serum concentration of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 2007, 115 , 2526–2532.

    Coojk S. , 'Serum concentration of uric acid and the metabolic syndrome among US children and adolescents ' (2007 ) 115 Circulation : 2526 -2532.

    • Search Google Scholar
  • Levenson, D.: Elevated uric acid: Could it be part of the metabolic syndrome. Clin. Lab. Strat., American Association of Clinical Chemistry, 2007, June 28.

  • Cameron, J. S.: Uric acid and renal disease. Nucleosid. Nucleotid. Nucleic Acids, 2008, 25 , 1055–1064.

    Cameron J. S. , 'Uric acid and renal disease ' (2008 ) 25 Nucleosid. Nucleotid. Nucleic Acids : 1055 -1064.

    • Search Google Scholar
  • Roncal, C. A., Mu, W., Croker, B. és mtsai: Effect of elevated serum uric acid on cisplantin induced acute renal failure. Am. J. Phys. Renal. Physiol., 2007, 292 , F116–F122.

    Croker B. , 'Effect of elevated serum uric acid on cisplantin induced acute renal failure ' (2007 ) 292 Am. J. Phys. Renal. Physiol. : F116 -F122.

    • Search Google Scholar
  • Sood, A. R., Burry, L. D., Cheng, D. K. E.: Claryfing the role of rasburicase in tumor lysis syndrome. Pharmacother., 2007, 27 , 111–121.

    Cheng D. K. E. , 'Claryfing the role of rasburicase in tumor lysis syndrome ' (2007 ) 27 Pharmacother. : 111 -121.

    • Search Google Scholar
  • Coiffier, B., Riouffol, C.: Management of tumor lysis syndrome. Expert Rev. Anticancer Ther., 2007, 7 , 233–239.

    Riouffol C. , 'Management of tumor lysis syndrome ' (2007 ) 7 Expert Rev. Anticancer Ther. : 233 -239.

    • Search Google Scholar
  • Montesinos, P., Lorenzo, I., Martin, G. és mtsai: Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Hematologica, 2008, 93 , 67–74.

    Martin G. , 'Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model ' (2008 ) 93 Hematologica : 67 -74.

    • Search Google Scholar
  • Tiu, R. V., Mountantonkis, S. E., Dunbar, A. J. és mtsai: Tumor lysis syndrome. Seminars Thromb. Hemostas., 2007, 33 , 397–407.

    Dunbar A. J. , 'Tumor lysis syndrome ' (2007 ) 33 Seminars Thromb. Hemostas. : 397 -407.

  • Truong, T. H., Beyene, J., Hitzler, J. és mtsai: Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer, 2007, 110 , 1832–1839.

    Hitzler J. , 'Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome ' (2007 ) 110 Cancer : 1832 -1839.

    • Search Google Scholar
  • McNutt, D. M., Holdsworth, M. T., Wong, C. és mtsai: Rasburicase for the management of tumor lysis syndrome. Annals Pharmacother., 2008, 40 , 1445–1450.

    Wong C. , 'Rasburicase for the management of tumor lysis syndrome ' (2008 ) 40 Annals Pharmacother. : 1445 -1450.

    • Search Google Scholar
  • Hummel, M., Reiter, S., Adam, K. és mtsai: Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur. J. Haematol., 2008, 80 , 331–339.

    Adam K. , 'Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase ' (2008 ) 80 Eur. J. Haematol. : 331 -339.

    • Search Google Scholar
  • Bertrand, Y., Mechinaud, F., Brethon, B. és mtsai: Recommendation for the management of tumor lysis syndrome (TLS) with rasburicase: An observation survey. J. Pediatr. Hematol., 2008, 30 , 267–271.

    Brethon B. , 'Recommendation for the management of tumor lysis syndrome (TLS) with rasburicase: An observation survey ' (2008 ) 30 J. Pediatr. Hematol. : 267 -271.

    • Search Google Scholar
  • Steel, S., Coutsouvelis, J., Mckendrick, J.: Single dose rasburicase in tumor lysis: One hospital’s experience. Asia-Pacific J. Clin. Oncol., 2008, 4 , 18–20.

    Mckendrick J. , 'Single dose rasburicase in tumor lysis: One hospital’s experience ' (2008 ) 4 Asia-Pacific J. Clin. Oncol. : 18 -20.

    • Search Google Scholar
  • Oldfield, V., Perry, C. M.: Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs, 2006, 20 , 197–199.

    Perry C. M. , 'Spotlight on rasburicase in anticancer therapy-induced hyperuricemia ' (2006 ) 20 BioDrugs : 197 -199.

    • Search Google Scholar
  • Renyi, I., Bardi, I., Udvardi, E. és mtsai: Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma. Pathol. Oncol. Res., 2007, 13 , 57–62.

    Udvardi E. , 'Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma ' (2007 ) 13 Pathol. Oncol. Res. : 57 -62.

    • Search Google Scholar
  • Moolenburgh, J. D., Reinders, M. K., Jansen, T. L.: Rasburicase treatment in severe tophaceous gout: a novel therapeautic option. Clin. Rheumatol., 2006, 25 , 749–752.

    Jansen T. L. , 'Rasburicase treatment in severe tophaceous gout: a novel therapeautic option ' (2006 ) 25 Clin. Rheumatol. : 749 -752.

    • Search Google Scholar
  • Sundy, J. S., Ganson, N. J., Kelly, S. J. és mtsai: Pharmacokinetics and pharmacodynamics of intravenous PEGylated mammalian urate oxidase in patients with refractory gout. Arthritis Rheum., 2007, 56 , 1021–1026.

    Kelly S. J. , 'Pharmacokinetics and pharmacodynamics of intravenous PEGylated mammalian urate oxidase in patients with refractory gout ' (2007 ) 56 Arthritis Rheum. : 1021 -1026.

    • Search Google Scholar
  • Stamp, L. K., O’Donnell, L. J., Chapman, P. T.: Emerging therapies in the long-term management of hyperuricemia and gout. Internal Med. J., 2007, 37 , 258–260.

    Chapman P. T. , 'Emerging therapies in the long-term management of hyperuricemia and gout ' (2007 ) 37 Internal Med. J. : 258 -260.

    • Search Google Scholar
  • Sherman, M. R., Saifer, M. G. P., Perez-Ruiz, F.: PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev., 2008, 60 , 59–68.

    Perez-Ruiz F. , 'PEG-uricase in the management of treatment-resistant gout and hyperuricemia ' (2008 ) 60 Adv. Drug Deliv. Rev. : 59 -68.

    • Search Google Scholar
  • Strand, V., Kimberly, R., Isaacs, J. D.: Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov., 2007, 6 , 75–92.

    Isaacs J. D. , 'Biologic therapies in rheumatology: lessons learned, future directions ' (2007 ) 6 Nat. Rev. Drug Discov. : 75 -92.

    • Search Google Scholar
  • Ronco, C., Inguaggiato, P., Bordoni, V. és mtsai: Rasburicase therapy in acute hyperuricemia and renal dysfunction. Contribut. Nephrol., 2005, 147 , 115–123.

    Bordoni V. , 'Rasburicase therapy in acute hyperuricemia and renal dysfunction ' (2005 ) 147 Contribut. Nephrol. : 115 -123.

    • Search Google Scholar
  • Bellingheri, G., Santaoro, D., Savica, V.: Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients. Contribut. Nephrol., 2005, 147 , 149–160.

    Savica V. , 'Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients ' (2005 ) 147 Contribut. Nephrol. : 149 -160.

    • Search Google Scholar
  • Méhes, L., Udvard, M., Szász, R. és mtsai: Az urát-nephropathia patofiziologiája, klinikuma és kezelése. Orv. Hetil., 2007, 148 , 745–748.

    Szász R. , 'Az urát-nephropathia patofiziologiája, klinikuma és kezelése ' (2007 ) 148 Orv. Hetil. : 745 -748.

    • Search Google Scholar
  • Pui, C. H.: Urate oxidase in the prophylaxis or treatment of hyperuricemia. Seminars Hematol., 2001, 38(S10) , 13–21.

    Pui C. H. , 'Urate oxidase in the prophylaxis or treatment of hyperuricemia ' (2001 ) 38 Seminars Hematol. : 13 -21.

    • Search Google Scholar
  • Patte, C., Sakiroglu, C., Ansoborlo, S. és mtsai: Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d’Oncologie Pediatrrique LM89 protocol. Annal. Oncol., 2002, 13 , 789–795.

    Ansoborlo S. , 'Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d’Oncologie Pediatrrique LM89 protocol ' (2002 ) 13 Annal. Oncol. : 789 -795.

    • Search Google Scholar
  • Mycyk, M., Manligod, J., Sigg, T. és mtsai: Methemoglobinemia induced by routine urate oxidase administration. J. Toxicol. Clin. Toxicol., 2001, 39 , 511.

    Sigg T. , 'Methemoglobinemia induced by routine urate oxidase administration ' (2001 ) 39 J. Toxicol. Clin. Toxicol. : 511 -.

    • Search Google Scholar
  • Browing, L., Krusse, J.: Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann. Pharmacother., 2005, 39 , 1932–1935.

    Krusse J. , 'Hemolysis and methemoglobinemia secondary to rasburicase administration ' (2005 ) 39 Ann. Pharmacother. : 1932 -1935.

    • Search Google Scholar
  • Kizer, N., Martinez, E., Powell, M.: Report of two cases of rasburicase-induced methemoglobinemia. Leukem. Lymph., 2006, 47 , 2648–2650.

    Powell M. , 'Report of two cases of rasburicase-induced methemoglobinemia ' (2006 ) 47 Leukem. Lymph. : 2648 -2650.

    • Search Google Scholar
  • Oldfield, V., Perry, C. M.: Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs, 2006, 20 , 197–199.

    Perry C. M. , 'Spotlight on rasburicase in anticancer therapy-induced hyperuricemia ' (2006 ) 20 BioDrugs : 197 -199.

    • Search Google Scholar
  • O’Connor, L. F, Scmid-Schonbein, G. W.: Plasma hydrogen peroxide production in hypertension subjects at genetic risk of hypertension. J. Hypertension, 1998, 16 , 291–303.

    Scmid-Schonbein G. W. , 'Plasma hydrogen peroxide production in hypertension subjects at genetic risk of hypertension ' (1998 ) 16 J. Hypertension : 291 -303.

    • Search Google Scholar
  • Góth L.: A hidrogén-peroxid paradoxon. Orv. Hetil., 2006, 147 , 887–893.

    Góth L. , 'A hidrogén-peroxid paradoxon ' (2006 ) 147 Orv. Hetil. : 887 -893.

  • Mueller, S., Reidel, H. D., Stremmer, W.: Direct evidence for catalase as the predominant H2O2 removing enzyme in human erythrocytes. Blood, 1997, 90 , 4973–4979.

    Stremmer W. , 'Direct evidence for catalase as the predominant H2O2 removing enzyme in human erythrocytes ' (1997 ) 90 Blood : 4973 -4979.

    • Search Google Scholar
  • Góth, L.: A szérum kataláz és a vér kataláz csökkenés veleszületett és szerzett formáinak patobiokémiai és genetikai vizsgálata Magyarországon. MTA, Doktori értekezés, 2006.

  • Góth, L., Vitai, M.: Hypocatalasemia in hospital patients. Clin. Chem., 1996, 42 , 341–342.

    Vitai M. , 'Hypocatalasemia in hospital patients ' (1996 ) 42 Clin. Chem. : 341 -342.

  • Góth L.: Öröklődő kataláz-enzimhiányos állapotok Magyarországon. Orv. Hetil., 2000, 141 , 445–447.

    Góth L. , 'Öröklődő kataláz-enzimhiányos állapotok Magyarországon ' (2000 ) 141 Orv. Hetil. : 445 -447.

    • Search Google Scholar
  • Hamada, Y., Kameyama, Y., Izuka, T. és mtsai: Methemoglobin from hydrogen peroxide in a patient with acatalasemia. Anesthesiology, 2004, 101 , 247–248.

    Izuka T. , 'Methemoglobin from hydrogen peroxide in a patient with acatalasemia ' (2004 ) 101 Anesthesiology : 247 -248.

    • Search Google Scholar
  • Takahara, S.: Progressive oral gangrene probably due to lack of catalase in the blood (acatalasemia). Lancet, 1952, 2 , 1101–1104.

    Takahara S. , 'Progressive oral gangrene probably due to lack of catalase in the blood (acatalasemia) ' (1952 ) 2 Lancet : 1101 -1104.

    • Search Google Scholar
  • Pfügler, G., Kaiser, E.: Acatalasia discovered by accident during a disc operation. Arch. Orthop. Trauma Surg., 1988, 107 , 189–190.

    Kaiser E. , 'Acatalasia discovered by accident during a disc operation ' (1988 ) 107 Arch. Orthop. Trauma Surg. : 189 -190.

    • Search Google Scholar
  • Góth, L., Bigler, W. N.: Catalase deficiency may complicate urate oxidase (rasburicase) therapy. Free Rad. Res., 2007, 41 , 963–955.

    Bigler W. N. , 'Catalase deficiency may complicate urate oxidase (rasburicase) therapy ' (2007 ) 41 Free Rad. Res. : 963 -955.

    • Search Google Scholar
  • Stove, V., Wuyts, B., Delanghe, J.: Perchloric acid treatment to stabilize uric acid concentrations of patients receiving uric acid oxidase (Rasburicase) treatment. Clin. Chem., 2007, 53 , 369–370.

    Delanghe J. , 'Perchloric acid treatment to stabilize uric acid concentrations of patients receiving uric acid oxidase (Rasburicase) treatment ' (2007 ) 53 Clin. Chem. : 369 -370.

    • Search Google Scholar

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu